Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains?
10:56am, Monday, 05'th Jan 2026
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
24,483 Shares in Corcept Therapeutics Incorporated $CORT Purchased by Stanley Laman Group Ltd.
07:04am, Monday, 05'th Jan 2026
Stanley Laman Group Ltd. acquired a new position in Corcept Therapeutics Incorporated (NASDAQ: CORT) in the third quarter, according to its most recent disclosure with the Securities and Exchange Comm
Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug
07:08am, Sunday, 04'th Jan 2026
Corcept Therapeutics (CORT) leverages Korlym's commercial success in hypercortisolism, generating $559.3M in nine-month 2025 revenue and $19M Q3 net income. Despite positive Phase 3 data, the FDA unex
Benzinga Bulls And Bears: Nike, SpaceX, Ultragenyx — And Chinese Tech Stocks Slide
09:01am, Saturday, 03'rd Jan 2026
Benzinga examined the prospects for many investors' favorite stocks over the last week - here's a look at some of our top stories.
Cwm LLC Purchases 16,304 Shares of Corcept Therapeutics Incorporated $CORT
05:04am, Saturday, 03'rd Jan 2026
Cwm LLC raised its position in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 135.9% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Excha
Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism
11:26am, Friday, 02'nd Jan 2026
CORT's shares plunge after the FDA issues a CRL to relacorilant's new drug application for treating patients with hypercortisolism.
Why Corcept Therapeutics Plummeted by 50% Today
06:21pm, Wednesday, 31'st Dec 2025
The FDA declined to approve its relacorilant. The regulator wrote that it lacked sufficient evidence from the biotech about the drug's effectiveness.
Why Corcept Therapeutics stock crashed today and what comes next?
04:02pm, Wednesday, 31'st Dec 2025
Corcept Therapeutics (NASDAQ: CORT) crashed about 50% on Dec. 31 after the FDA requested additional data to support the efficacy of relacorilant, its candidate treatment for Cushing's syndrome. The se
Corcept Therapeutics Shares Drop 50% After FDA Rejects Drug
12:31pm, Wednesday, 31'st Dec 2025
The FDA cited insufficient evidence of effectiveness for relacorilant in patients with Cushing syndrome and hypertension, sending the stock sharply lower.
US FDA declines to approve Corcept's drug for rare hormonal disorder
08:05am, Wednesday, 31'st Dec 2025
The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' hormone-blocking drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
08:00am, Wednesday, 31'st Dec 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
Abacus FCF Advisors LLC Acquires Shares of 38,961 Corcept Therapeutics Incorporated $CORT
03:12am, Tuesday, 30'th Dec 2025
Abacus FCF Advisors LLC bought a new position in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) during the undefined quarter, according to the company in its most recent filing with the SE
Ellsworth Advisors LLC Invests $769,000 in Corcept Therapeutics Incorporated $CORT
05:18am, Saturday, 27'th Dec 2025
Ellsworth Advisors LLC purchased a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) during the third quarter, according to the company in its most recent 13F filing with the Sec
Burney Co. Sells 19,381 Shares of Corcept Therapeutics Incorporated $CORT
04:28am, Saturday, 27'th Dec 2025
Burney Co. lessened its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) by 7.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Co
Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?
11:41am, Monday, 22'nd Dec 2025
Are There Red Flags in the Trial Results?
